HSHideshi Sugiura

Hideshi Sugiura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hideshi Sugiura has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The clinical outcome of pazopanib treatment for soft tissue sarcomas: A Japanese Musculoskeletal Oncology Group study

    by Akihiko Matsumine, Tomoki Nakamura, Akira Kawai, Nobuhito Araki, Takahiro Goto, Tsukasa Yonemoto, Hideshi Sugiura, Yoshihiro Nishida, Hiroaki Hiraga, Takafumi Ueda

    Soft tissue sarcomas (STSs) are a rare and heterogeneous group of tumors that include more than 50 histological types. Five to thirty percent of STS patients have a local recurrence and 10-38% present with clinically detectable metastases. However, the development of new systemic treatments for patients with STSs has been limited in the past few decades.

  • A randomized phase II study comparing trabectedin (T) and best supportive care (BSC) in patients (pts) with translocation-related sarcomas (TRS).

    by Shunji Takahashi, Nobuhito Araki, Hideshi Sugiura, Takafumi Ueda, Mitsuru Takahashi, Hideo Morioka, Tsukasa Yonemoto, Hiroaki Hiraga, Toru Hiruma, Toshiyuki Kunisada, et al.

    10524 Background: T binds to the minor groove of DNA and blocks DNA repair machinery following the inhibition of cell cycle and proliferation. In addition, T inhibits interactions of transcription factors including TRS-related transcription factors with the DNA in a competitive manner. This is the first time that the progression-free survival (PFS) of T is compared with BSC as a second or later line treatment in pts with TRS in a multi-center, open, phase II trial. Methods: Main inclusion criteria were the following: histologically proven TRS; unresponsiveness or intolerability to standard chemotherapy regimens (pts with extraskeletal Ewing sarcoma (EES), myxoid liposarcoma (ML), or synovial sarcoma (SS) should have received anthracyclines); at least 1 measurable baseline lesion (RECIST v1.1); confirmed disease progression (per RECIST) compared with the image assessment performed during the previous 6 months(m). Pts stratified by subtype (alveolar rhabdomyosarcoma, ESS, ML, SS vs other TRS) were randomly assigned 1:1 to T (1.2 mg/m2 in 24h continuous infusion every 21 days) or BSC. The primary endpoint was PFS by independent review assessment (IR). This study had 80% power for a one-sided 5% significance level test given a hazard ratio (HR) (T relative to BSC) of 0.50. Sample size goal was 74 pts with an event goal of 52 events by IR requiring a total of 60 events by investigator’s assessment (IA). PFS and overall survival (OS) were analyzed using a stratified log-rank test. Results: Data cut-off date was 8th February 2014. Total of 76 pts were enrolled. Number of pts for efficacy analysis was 73 (T: 37 pts and BSC: 36 pts). Median PFS (90% confidence interval(CI))for T and BSC were 5.6 m (4.2-7.5) and 0.9 m (0.9-1.0), respectively (p<0.0001; HR=0.07, 90% CI: 0.03-0.14). Median OS (95% CI) for T and BSC were not reached (NR) (12.8-NR) and 8.0 m (7.0-NR), respectively (p=0.025; HR=0.38, 95% CI: 0.16-0.91) under permission of crossover. Conclusions: T is an active drug in TRS pts pretreated by available chemotherapies with a significant increase in PFS and OS. Clinical trial information: JapicCTI-121850.


    • 20 May 2010
      • Vol. 95  (1) , 33-9

    Oncologic and functional outcomes of soft tissue sarcomas of the distal upper extremity: comparison with those of the proximal upper extremity.

    by Yoshihisa Yamada, Yoshihiro Nishida, Hiroatsu Nakashima, Hideshi Sugiura, Satoshi Tsukushi, Yuzuru Kamei, Kazuhiro Toriyama, Naoki Ishiguro

    To determine the factors predicting the oncologic and functional outcomes in patients with distal upper extremity soft tissue sarcomas, and to compare functional outcomes with those occurring in the proximal upper extremity, 28 consecutive patients with a soft tissue sarcoma in a distal upper extremity (group I) and 20 patients with one in a proximal upper extremity (group II) were surgically treated. The 5-year survival rate in patients with soft tissue sarcomas at distal and proximal locations were 74% and 87% for local recurrence, 84% and 66% for metastasis free, and 89% and 66% for overall, respectively. A significant adverse prognostic factor for local recurrence was deep location (P < 0.01). For metastasis-free and overall survival, adjuvant therapy (P < 0.001) and high-grade malignancy (P < 0.01) were significant poor prognostic factors. Deep location (P = 0.02) and prereferral surgery (P = 0.02) correlated with poorer function as reflected in the Musculoskeletal Tumor Society (MSTS) and Disabilities of the Arm, Shoulder, and Hand (DASH) functional scores, respectively. Patients in groups I and II showed good oncologic and functional outcomes. In group I patients, high-grade malignancy, adjuvant chemotherapy, and deep location were poor oncologic factors, and deep location and prereferral surgery were adverse prognostic factors for functional score.


  • Predictors of Survival in Patients With Bone Metastasis of Lung Cancer

    by Hideshi Sugiura, Kenji Yamada, Takahiko Sugiura, Toyoaki Hida, Tetsuya Mitsudomi

    E 59.9% at 6 months, 31.6% at 1 year, and 11.3% at 2 years. The mean survival was 9.7 months (median, 7.2 months; range, 0.1-74.5 months). A favorable prognosis was more likely in women and patients with adenocarcinoma, solitary bone metastasis, no metastases to the appendicular bone, no pathologic fractures, performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor. Analyses of single and multiple variables indicated better prognoses for patients with adenocarcinoma, no evidence of appendicular bone metastases, and treatment with an epithelial growth factor receptor inhibitor. The mean survival period was longer in a small group treated with an epithelial growth factor receptor inhibitor than in the larger untreated group. The data preliminarily suggest treatment with an epithelial growth factor receptor inhibitor may improve survival after bone metastasis. Level of Evidence: Level IV, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence....


    • 1 October 2007
      • Vol. 36  (10) , E151-2

    Synovial osteochondromatosis of the carpometacarpal joint.

    by Hiroatsu Nakashima, Hideshi Sugiura, Yoshihiro Nishida, Yoshihisa Yamada, Naoki Ishiguro


  • Pasteurized Intercalary Autogenous Bone Graft Combined with Vascularized Fibula

    by Hideshi Sugiura, Mitsuru Takahashi, Keisuke Nakanishi, Yoshihiro Nishida, Yuzuru Kamei

    The optimal reconstruction procedure after wide resection of bone tumors is debatable. We reviewed pasteurized intercalary autogenous bone graft combined with a vascularized fibula graft in 15 patients with malignant bone tumors, and assessed whether this procedure would improve bone union and function. The mean duration until bone union of the pasteurized autogenous bone was 13.5 months and duration until union of the vascularized fibula was 7.7 months. Complete bone union between the pasteurized autogenous bone and the vascularized fibula eventually was achieved in 13 patients (86.7%). In the remaining two patients, fibula union was achieved but union of the pasteurized autogenous bone was not attributable to infection. Postoperative complications included two fractures and two infections. Three patients with delayed union eventually achieved bone union using an autogenous cancellous bone graft. The mean Musculoskeletal Tumor Society score was 80.6% and it was comparable to scores from other procedures. Our results suggest a pasteurized autogenous bone graft combined with a vascularized fibula graft can be a useful reconstruction method in selected patients with large bone defects after wide resection of malignant bone tumors. Level of Evidence: Level IV, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.


    • 1 November 2004
      • Vol. 31  (12) , 2065-8

    [A case of retroperitoneal neuroblastoma in an adult with extensive bone marrow metastasis].

    by Kenji Yamada, Hideshi Sugiura, Yoshitaka Suzuki, Mitsuru Takahashi

    We present a case of retroperitoneal neuroblastoma in a 27-year-old male with extensive bone marrow metastasis at the first presentation. After the simple excision of the tumor, adjuvant multi-drug chemotherapy, consisting of vincristine, actinomycin-D, ifosfamide, doxorubicin, carboplatin and etoposide, was carried out for 17 months, leading to complete remission. Ten months after completion of the chemotherapy, the tumor recurred with bone marrow metastasis. He further developed thoracic vertebral metastases resulting in paraplegia, and died of the disease 41 months after the presentation. The clinical course of this case, with its emphases especially on the effect of the chemotherapy, is described in this report. Since the clinical characteristics and treatment strategies for adult neuroblastoma have not yet been well established, they remain to be investigated in detail.

    • 1 January 2004
      • Vol. 31  (1) , 110-9

    Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in pigmented villonodular synovitis suggests their potential role for joint destruction.

    by Mitsutoshi Uchibori, Yoshihiro Nishida, Izuru Tabata, Hideshi Sugiura, Hiroatsu Nakashima, Yoshihisa Yamada, Naoki Ishiguro

    Pigmented villonodular synovitis (PVNS) is an uncommon idiopathic, proliferative synovial disease. Since matrix metalloproteinases (MMP) are assumed to play an important role in the pathogenesis of PVNS, we examined the expression and activity of MMP and tissue inhibitor of metalloproteinases (TIMP) in PVNS. Synovial tissue samples were obtained from 10 patients with PVNS (knee 8, ankle 2) and 4 patients each with rheumatoid arthritis (RA) or osteoarthritis (OA) for comparison. Protein deposition and mRNA expression were determined by conventional immunohistochemical studies and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Gelatin zymography was performed for detection of gelatin-degrading activity. The quantity of MMP and TIMP was measured by ELISA. Intense immunostaining for MMP-1 was detected in both the multinucleated giant cells and mononuclear cells, whereas TIMP-1 was weakly positive. MMP-9 immunostained predominantly in the multinucleated cells, whereas other MMP and TIMP were weakly detected. RT-PCR analysis showed that mRNA expression of MMP-9 was stimulated in PVNS, whereas MMP-2 mRNA was not, compared to RA or OA. The gelatin zymogram indicated protease activities predominantly at 92 kDa and 67 kDa. In accord with the immunostaining results, the amount of MMP-1 and MMP-9 protein was significantly higher than that of TIMP-1 and MMP-2, respectively. We characterized the expression and activity of MMP in PVNS and observed that PVNS tissues predominantly produce MMP-1 and MMP-9. Given that PVNS occasionally induces joint destruction, stimulated expression of MMP-1 and MMP-9 may contribute to the invasive activity and the bone and cartilage loss in PVNS.


  • Remodelling and healing process of moderately heat-treated bone grafts after wide resection of bone and soft-tissue tumors

    by H. Sugiura, S. Yamamura, K. Sato, H. Katagiri, Y. Nishida, H. Nakashima, Y. Yamada

    In the reconstruction of extensive bone defects after massive resection of malignant musculoskeletal tumors, the clinical results of moderately heat-treated autogenous bone graft have rarely been documented. We evaluated the remodelling and healing process of moderately heat-treated autogenous bone graft by means of imaging features.